Correction for Blasco-Benito et al., Therapeutic targeting of HER2–CB2R heteromers in HER2-positive breast cancer

PHARMACOLOGY Correction for “Therapeutic targeting of HER2–CB2R heteromers in HER2-positive breast cancer,” by Sandra Blasco-Benito, Estefanía Moreno, Marta Seijo-Vila, Isabel Tundidor, Clara Andradas, María M. Caffarel, Miriam Caro-Villalobos, Leyre Urigüen, Rebeca Diez-Alarcia, Gema Moreno-Bueno, Lucía Hernández, Luis Manso, Patricia Homar-Ruano, Peter J. McCormick, Lucka Bibic, Cristina Bernadó-Morales, Joaquín Arribas, Meritxell Canals, Vicent Casadó, Enric I. Canela, Manuel Guzmán, Eduardo Pérez-Gómez, and Cristina Sánchez, which was first published February 7, 2019; 10.1073/pnas.1815034116 (Proc Natl Acad Sci USA 116:3863–3872).

The authors note that, due to a printer’s error, the affiliation for Lucka Bibic appeared incorrectly. It should instead appear as School of Pharmacy, University of East Anglia, Norwich, Norfolk NR4 7TJ, United Kingdom. The corrected author and affiliation lines appear below. The online version has been corrected.

Sandra Blasco-Benito^a,b, Estefanía Moreno^c,d,e, Marta Seijo-Vila^a,b, Isabel Tundidor^a,b, Clara Andradas^a, María M. Caffarel^f,g, Miriam Caro-Villalobos^a,b, Leyre Urigüen^h,i, Rebeca Diez-Alarcia^h,i, Gema Moreno-Bueno^j,k,l,m,n, Lucía Hernández^b,o, Luis Manso^b,p, Patricia Homar-Ruano^c,d,e, Peter J. McCormick^q, Lucka Bibic^q, Cristina Bernadó-Morales^n,r, Joaquín Arribas^n,r,s, Meritxell Canals^t, Vicent Casadó^c,d,e, Enric I. Canela^c,d,e, Manuel Guzmán^a,e,u, Eduardo Pérez-Gómez^a,b, and Cristina Sánchez^a,b

^aDepartment of Biochemistry and Molecular Biology, Complutense University, 28040 Madrid, Spain; ^bInstituto de Investigación Hospital 12 de Octubre, 28041 Madrid, Spain; ^cDepartment of Biochemistry and Molecular Biomedicine, University of Barcelona, 08028 Barcelona, Spain; ^dInstitute of Biomedicine, University of Barcelona, 08028 Barcelona, Spain; ^eCentro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain; ^fBasque Foundation for Science (IKERBASQUE), 48013 Bilbao, Spain; ^gMolecular Oncology Group, Biodonostia Health Research Institute, 20014 San Sebastian, Spain; ^hDepartment of Pharmacology, University of the Basque Country Universidad del País Vasco/Euskal Herriko Unibersitatea, 48940 Leioa, Spain; ⁱCentro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), 28029 Madrid, Spain; ^jDepartment of Biochemistry, Universidad Autónoma de Madrid (UAM), 28049 Madrid, Spain; ^kInstituto de Investigaciones Biomédicas “Alberto Sols,” Consejo Superior de Investigaciones Científicas-UAM, 28029 Madrid, Spain; ^lInstituto de Investigación Hospital Universitario La Paz (IdiPAZ), 28046 Madrid, Spain; ^mFundación MD Anderson Internacional, 28033 Madrid, Spain; ⁿCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain; ^oPathology Unit, Hospital 12 de Octubre, 28041 Madrid, Spain; ^pMedical Oncology Department, Hospital 12 de Octubre, 28041 Madrid, Spain; ^qSchool of Pharmacy, University of East Anglia, Norwich, Norfolk NR4 7TJ, United Kingdom; ^rPreclinical Research Program, Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain; ^sDepartment of Biochemistry and Molecular Biology, Institució Catalana de Recerca i Estudis Avançats, Universitat Autónoma de Barcelona, 08193 Barcelona, Spain; ^tMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia; and ^uInstituto Ramón y Cajal de Investigación Sanitaria, 28034 Madrid, Spain